Share on StockTwits

Equities Research Analysts’ ratings reiterations for Friday, July 4th:

Align Technology (NASDAQ:ALGN) had its neutral rating reaffirmed by analysts at Zacks. They currently have a $60.00 target price on the stock. Zacks’ analyst wrote, “Align’s first-quarter 2014 results surpassed the Zacks Consensus Estimate on both fronts. Along with revenues, earnings per share (EPS) remained above the guidance range. Growth was boosted by strong Invisalign sales from international doctors in EMEA and also the Asia Pacific regions. Continued expansion of the company’s customer base and increased Invisalign utilization also propelled growth. Moreover, we are impressed with the company’s recent introduction of Invisalign G5, a new feature enhancement. We expect these to improve ASP going forward. The company’s solid focus on international markets and conversion of countries to direct sales geographies is encouraging. However, we are worried about the ongoing macroeconomic headwinds which continue to cast a negative impact on dental procedures. We are thus Neutral on Align.”

Amsurg Corp (NASDAQ:AMSG) had its neutral rating reissued by analysts at Zacks. They currently have a $51.00 target price on the stock. Zacks’ analyst wrote, “AmSurg’s fourth-quarter 2013 adjusted EPS of $0.53 increased 1.9% year over year but lagged the Zacks Consensus estimate by $0.02. It also remained at the low end of the company provided guidance range. Revenues increased a mere 1.9% and failed to meet the estimate. However, growth through strong performances of the acquired centers was encouraging. Furthermore, the Sheridan Healthcare acquisition plan, paving its way into the huge and fast-growing fragmented physician outsourcing market is expected to be a material upside. Nonetheless, headwinds like reduction in workers’ compensation reimbursement, sequestration and increased interest expense are intimidating. We are Neutral on AmSurg.”

ARRIS Group (NASDAQ:ARRS) had its outperform rating reaffirmed by analysts at Zacks. The firm currently has a $39.00 target price on the stock. Zacks’ analyst wrote, “Arris posted strong first-quarter 2014 financial results with both the top and the bottom line surpassing the Zacks Consensus Estimate. Strong demand for home gateways, major contract wins, and the acquisition of the cable set-top box business of Motorola Mobility has transformed the company into an integrated equipment supplier in the high-speed video and Internet delivery market. In addition, acquisition of SeaWell Networks will further help Arris enhance its product portfolio with offerings like IP video, multiscreen video and ad insertion solutions. Moreover, Arris has also raised the guidance for the second quarter of 2014. We, thus, upgrade our recommendation on Arris to Outperform from Neutral. “

Ashmore Group plc (LON:ASHM) had its equal weight rating reiterated by analysts at Barclays. They currently have a GBX 360 ($6.13) target price on the stock.

Bayer AG (NASDAQ:BAYRY) had its neutral rating reissued by analysts at Zacks. They currently have a $152.00 price target on the stock. Zacks’ analyst wrote, “Bayer’s earnings per share during the first quarter of 2014 came in at 1.95 (approx. $2.67) compared with 1.70 (approx. $2.25) in the year-ago period. Bayer expects 2014 sales of around 41- 42 billion, an increase of 5% from the 2013 figure. The company’s new drugs performed impressively in the first quarter of 2014 and are expected to do so in the coming quarters as well. We are also pleased with Bayer’s impending acquisition of Merck’s consumer health unit. However, we remain concerned about the company’s Material Science segment, which has performed below par over the last few quarters. We maintain our Neutral stance on the stock.”

Bed Bath & Beyond (NASDAQ:BBBY) had its neutral rating reaffirmed by analysts at Zacks. Zacks currently has a $62.00 price target on the stock. Zacks’ analyst wrote, “Bed Bath & Beyond posted dismal first-quarter fiscal 2014 results, wherein both top and bottom line fell short of the Zacks Consensus Estimate. The lower-than-expected earnings performance was due to a challenging retail environment, soft sales and increased costs because of the ongoing long-term investments. Moreover, the company provided a cautiously optimistic guidance for the second quarter and fiscal 2014. Though the near-term outlook appears to be bleak, we believe the company’s strategic initiatives toward expanding its store base, investments in improving customer service and progress in online sales show potential. Based on a rebound in the housing market, we expect the company to grow at an impressive pace. Given the pros and cons, we maintain our Neutral stance on the stock.”

Basf Se (NYSE:BF) had its neutral rating reissued by analysts at Zacks. Zacks currently has a $99.00 target price on the stock. Zacks’ analyst wrote, “We remain impressed with Brown-Forman’s strong top and bottom-line growth for the fourth quarter and fiscal 2014 as well as management’s optimistic outlook for fiscal 2015. We believe that Brown-Forman’s consistent focus on developing its premium Jack Daniel’s brand through innovation and packaging changes has paid off, making it a thriving company. Moreover, we expect its pricing strategy, product innovation and penetration in emerging markets to boost operational performance. However, stiff competition and risks arising from operating in the overseas markets may adversely impact its performance. Furthermore, we are cautious as any increase in excise tax could dent the company’s financial performance as distilled spirits are subject to excise tax in various countries. Hence, our long-term Neutral recommendation on the stock remains in place.”

BioMarin Pharmaceutical (NASDAQ:BMRN) had its neutral rating reissued by analysts at Zacks. They currently have a $68.00 target price on the stock. Zacks’ analyst wrote, “BioMarin’s first quarter 2014 loss of $0.27 per share (including stock based compensation expense) was narrower than the Zacks Consensus Estimate of a loss of $0.50. Higher-than-expected revenues led to the narrower-than-expected loss. Total revenues (on an adjusted basis) climbed 19% to $155.3 million due to higher net product sales. The EU approval of Vimizim in April is a positive for BioMarin as the market has a greater population of MPS IVA patients compared to the U.S. where the drug was cleared in Feb 2014. We however see limited upside from current levels until more visibility is obtained on Vimizim’s progress and hence retain our neutral stance on the stock. Our target price is $68.00 per share.”

BOK Financial (NASDAQ:BOKF) had its neutral rating reaffirmed by analysts at Zacks. Zacks currently has a $71.00 price target on the stock. Zacks’ analyst wrote, “BOK Financial’s first-quarter 2014 earnings outpaced the Zacks Consensus Estimate. Results were aided by lower expenses, partially offset by reduced revenues. Increase in loans and deposits were the positives. The company completed the acquisition of Houston-based MBM Advisors in Apr 2014. We believe the company’s diverse revenue mix and favorable geographic footprint will drive further growth. In fact, strategic expansions and a local leadership-based business model helped the company to transform from a bank in Oklahoma to a leading financial service provider. However, a low interest environment, regulatory pressures and risks emanating from its private label mortgage backed securities portfolio remain concerns.”

Cincinnati Bell (NYSE:CBB) had its neutral rating reissued by analysts at Zacks. Zacks currently has a $4.25 price target on the stock. Zacks’ analyst wrote, “We believe that Cincinnati Bell is poised to deliver stable financial performance in the months ahead, owing to its investment in strategic products, high speed Internet and strong managed service demand. The company’s Wireline segment stands as the prime growth driver with strength in the Fioptics business from continuous fiber deployment. Further, the acquisition of CyrusOne will support high demand for data center colocation service. However, erosion in local access lines due to fierce competition poses a major roadblock in the company’s growth path. Cincinnati Bell is also winding down its wireless operation amid constant subscriber loss to national carriers, thus removing a recurring revenue stream. Hence, we expect the stock to perform on par with the broader market and adhere to our Neutral recommendation.”

CBOE Holdings (NASDAQ:CBOE) had its neutral rating reiterated by analysts at Zacks. They currently have a $51.00 target price on the stock.

Canadian Pacific Railway Limited (NYSE:CP) had its neutral rating reissued by analysts at Zacks. The firm currently has a $192.00 price target on the stock.

Dun & Bradstreet Corp. (NYSE:DNB) had its neutral rating reissued by analysts at Zacks. Zacks currently has a $118.00 price target on the stock. Zacks’ analyst wrote, “D&B reported mixed first-quarter 2014 results. Although earnings surpassed the Zacks Consensus Estimate, revenues lagged the same. The company provided cautious revenue guidance due to sluggish growth prospect of the core risk management solution business. The company continues to upgrade its core DNBi solution to cloud, which will attract customers over the long term. However, this transition will affect top-line growth in the near term. Moreover, additional investments in cloud upgrade will hurt profitability. Further, a highly leveraged balance sheet and intense competition are the major headwinds. Nevertheless, we believe that D&B’s high-margin business model, strong international growth potential, strategic investments, partnerships with Salesforce.com, SugarCRM and First Rain, accretive cloud-based acquisitions and aggressive share buyback will drive growth in the long run. We maintain our Neutral recommendation on the stock and set a price target of $118.00.”

Domino's Pizza (NYSE:DPZ) had its neutral rating reiterated by analysts at Zacks. The firm currently has a $77.00 price target on the stock. Zacks’ analyst wrote, “Domino’s Pizza posted solid first quarter 2014 results. Adjusted earnings of $0.68 per share beat the Zacks Consensus Estimate by 3.0% and were up 15.3% year over year owing to higher revenues, margin expansion and lower share count. Revenues surpassed the consensus mark by 3.0% and increased 15.3% year over year driven by improved domestic and international comps. Domino’s Pizza has been posting impressive results for the past few quarters on the back of higher traffic at its restaurants and unit growth. The company’s international operations promise significant growth potential. We believe the company’s digital ordering system and its foray into the Pan Pizza and Specialty Chicken categories will help it to sustain the top line momentum. However, increase in commodity costs remain a concern. Moreover, a weak consumer spending environment owing to macroeconomic pressure is also a headwind. We maintain our Neutral recommendation on the stock.”

Hays plc (LON:HAS) had its overweight rating reissued by analysts at Barclays. Barclays currently has a GBX 190 ($3.24) price target on the stock.

Halfords Group plc (LON:HFD) had its equal weight rating reiterated by analysts at Barclays. The firm currently has a GBX 460 ($7.84) price target on the stock.

Hilltop Holdings (NYSE:HTH) had its neutral rating reissued by analysts at Zacks. They currently have a $23.00 price target on the stock.

Incyte (NASDAQ:INCY) had its neutral rating reaffirmed by analysts at Zacks. Zacks currently has a $58.00 price target on the stock. Zacks’ analyst wrote, “Incyte reported a loss of $0.21 per share in the first quarter of 2014, wider than the Zacks Consensus Estimate of a loss of $0.19 and the year-ago loss of $0.12 per share. The wider loss was due to higher expenses. Jakafi has performed well since its launch for MF and is expected to keep doing so going forward. We are encouraged by the company’s efforts to expand Jakafi’s label, primarily for the polycythemia vera indication. The company’s deals with AstraZeneca and Bristol-Myers are also encouraging. Successful label expansion of the drug should drive growth further. Meanwhile, we are concerned about the company’s over-dependence on a single product for growth. We maintain our Neutral recommendation on the stock.”

Marks and Spencer Group Plc (LON:MKS) had its underweight rating reiterated by analysts at Barclays. They currently have a GBX 340 ($5.79) price target on the stock.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.